Voya Investment Management LLC Sells 12,210 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Voya Investment Management LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 54,362 shares of the medical equipment provider’s stock after selling 12,210 shares during the quarter. Voya Investment Management LLC’s holdings in Zimmer Biomet were worth $5,355,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ZBH. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $204,000. Wellington Management Group LLP increased its holdings in shares of Zimmer Biomet by 230.6% in the first quarter. Wellington Management Group LLP now owns 36,865 shares of the medical equipment provider’s stock worth $4,172,000 after acquiring an additional 25,713 shares in the last quarter. CW Advisors LLC raised its position in shares of Zimmer Biomet by 8.2% during the first quarter. CW Advisors LLC now owns 3,123 shares of the medical equipment provider’s stock worth $353,000 after purchasing an additional 236 shares during the period. Comerica Bank increased its stake in Zimmer Biomet by 36.3% during the 1st quarter. Comerica Bank now owns 46,206 shares of the medical equipment provider’s stock worth $5,230,000 after purchasing an additional 12,311 shares in the last quarter. Finally, Vident Advisory LLC lifted its stake in Zimmer Biomet by 101.6% in the first quarter. Vident Advisory LLC now owns 14,088 shares of the medical equipment provider’s stock valued at $1,595,000 after buying an additional 7,099 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the subject of a number of research reports. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a report on Wednesday, November 5th. Canaccord Genuity Group lowered their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Citigroup cut their price target on shares of Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a research report on Thursday, December 11th. Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price objective for the company. Finally, BTIG Research dropped their target price on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $107.50.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $90.23 on Thursday. Zimmer Biomet Holdings, Inc. has a 12-month low of $85.33 and a 12-month high of $114.44. The firm has a market capitalization of $17.88 billion, a price-to-earnings ratio of 22.33, a P/E/G ratio of 2.35 and a beta of 0.61. The stock’s 50 day moving average price is $94.49 and its two-hundred day moving average price is $96.63. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The business had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the prior year, the business earned $1.74 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.76%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.